An investigation was announced for investors in NASDAQ:EXAS shares concerning potential breaches of fiduciary duties by certain officers and directors at EXACT Sciences.
Investors who purchased shares of EXACT Sciences Corporation (NASDAQ:EXAS) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain EXACT Sciences directors breached their fiduciary duties and caused damage to the company and its shareholders.
On May 15, 2017, a reprot was published on EXACT Sciences Corporation and stated, “Exact Sciences pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.” Cologuard is a branded laboratory-based scan for DNA traces in stool samples, indicating colorectal cancer. The report mentioned a recent account from United Healthcare, that disapproved of the use of fecal DNA testing for colorectal cancer screening and monitoring, and found it to be “unproven and not medically necessary.” The article stated that “key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.” The article continued to say that “Poop in a box will probably be a medical dinosaur in 4 years and the value of Exact’s only asset will be 0.” Shares of EXACT Sciences Corporation (NASDAQ:EXAS) declined on May 18, 2017 to $29.45 per share.
Those who purchased NASDAQ:EXAS shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego